HOME >> MEDICINE >> NEWS
AMPAKINE compounds a new potential treatment for respiratory depression

was intended.

The drug tested in this study belongs to a novel class of molecules known as AMPAKINE compounds being developed by Cortex Pharmaceuticals, Inc. located in Irvine, California. AMPAKINE compounds act on the most common excitatory receptor in the brain, the AMPA "Glutamate type receptor," which has been shown in rodent models to boost the brain's own protein for improving age-related deficits in memory mechanisms. In primate models AMPAKINE compounds have replicated the studies in rodents and in adults patients suffering from Attention Deficit Hyperactivity Disorder, significant clinical and statistical improvement in increase attention and decrease hyperactivity have been observed. The U. Alberta research provide evidence that another important AMPAKINE indication is to stimulate primitive areas of the brain called the pre-Botzinger Complex responsible for breathing, without causing side effects. The pre-Botzinger Complex generated respiratory-related oscillations similar to those generated by the whole brainstem in vitro, and neurons with voltage-dependent pacemaker-like properties that have been identified in this brain region.

In a study published in 2006, Dr. John J. Greer of U. Alberta demonstrated that certain AMPAKINE compounds enhance the respiratory drive and breathing rhythm at the brain-stem level containing the pre-Botzinger Complex in laboratory rats whose respiration rates were purposely suppressed by administration of central nervous system depressants.

Dr. Greer found that respiratory depression induced by these agents can be reversed or prevented in test animals with an experimental AMPAKINE drug, without a reduction of pain relief or sedation.

Greer and coworkers treated rats with the opioids analgesic fentanyl or the barbiturate sedative Phenobarbital, both commonly prescribed in the United States. Greer used a technique known as plethysmography, which measures blood flow throughout
'"/>

Contact: Mark Varney
mvarney@cortexpharm.com
949-231-0672
Cortex Pharmaceuticals
4-Jun-2007


Page: 1 2 3 4 5

Related medicine news :

1. New oxidation methods streamline synthesis of important compounds
2. Depression among retired NFL players: Rates mirror the general public, but pain compounds symptoms
3. U of M researchers discover compounds to shrink tumors
4. Diagnosis and treatment of osteoporosis falls shortnon adherence compounds issue
5. New compounds fight chronic symptoms of bowel disorders
6. New synthetic compounds appear to prevent brain cell death
7. Phenolic compounds may explain Mediterranean diet benefits
8. Vitamin D compounds show promise for prevention of prostate cancer
9. Hebrew University researcher develops compounds to control bacteria
10. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
11. Electric fields have potential as a cancer treatment

Post Your Comments:
(Date:5/22/2015)... 2015 Carnegie Science Center ... a new partnership to develop BodyTech, a dynamic, three-pronged ... initiative includes a new exhibit at the Science Center ... and a new traveling science show, Anatomy Adventure, which ... , Designed to explore a wide range of ...
(Date:5/22/2015)... Boston, Massachusetts (PRWEB) May 22, 2015 ... conditions is a difficult process. Historically providers have ... efforts by payers. Starting in 2015, Medicare has ... care coordination activities. Thanks to the launch of ... technology, providers and health systems using the platform ...
(Date:5/22/2015)... Memorial Day weekend is typically considered the beginning of ... tips to help promote safe travel. , According to estimates ... fatalities this Memorial Day weekend. Amica is sharing the following ... , , Always wear a seatbelt: ... whether they’re driving or riding along as a passenger. Seatbelts ...
(Date:5/22/2015)... Seattle, WA (PRWEB) May 22, 2015 According ... adults of all generations are equally as likely to worry ... (72% Millennials, 75% Gen X, 77% Boomers, 69% Silent Generation), ... (45%) agree they are scared of aging, particularly Millennials (47%), ... online by Harris Poll in April, 2015 among more than ...
(Date:5/22/2015)... Power Systems is proud to announce the ... season. Drobeck is in his second year of racing in ... the Missoula Fire Department in Missoula, MT. He entered the ... During his career, he has had 15 1st Place finishes. ... 10 finishes in all seven of his 2014 races, including ...
Breaking Medicine News(10 mins):Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4Health News:Oculus Health Care Coordination Platform Officially Launched 2Health News:Oculus Health Care Coordination Platform Officially Launched 3Health News:Oculus Health Care Coordination Platform Officially Launched 4Health News:Amica Has 4 Road Safety Tips for Memorial Day Weekend 2Health News:New Study Reveals America’s Fear of Aging 2Health News:New Study Reveals America’s Fear of Aging 3
(Date:5/22/2015)... May 22, 2015  The U.S. Food and ... -- the first biosimilar product approved in ... toward growth in the contract manufacturing organization (CMO) ... industry is geared to the production of small-molecular ... biopharmaceutical products. The healthcare market research publisher,s report, ...
(Date:5/22/2015)... YORK and KING OF PRUSSIA, Pa. ... Foundation (NHF) has awarded CSL Behring its ... and unwavering commitment to advancing science and improving the care ... Paul Perreault , CEO and Managing Director, CSL Limited, ... York City on May 21. "The ...
(Date:5/22/2015)... ROCKVILLE, Md. , May 22, 2015 /PRNewswire/ ... "RegeneRx") today announced a peer-reviewed publication of the ... study evaluating RGN-259 (RegeneRx,s preservative-free eye drops) for ... Inc.,s controlled adverse environment (CAE ® ) model.  ... and the results, which were previously disseminated by ...
Breaking Medicine Technology:Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 2National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 4Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4
Cached News: